We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

BECKMAN COULTER, INC.

  Gold Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Developing Tests to Detect Coronavirus Antibodies

By LabMedica International staff writers
Posted on 01 Apr 2020
Print article
Image: Immunoassay Analyzer Access 2 (Photo courtesy of Beckman Coulter)
Image: Immunoassay Analyzer Access 2 (Photo courtesy of Beckman Coulter)
Beckman Coulter (Brea, CA, USA) has responded to the global COVID-19 pandemic by developing assays to identify IgM and IgG antibodies to the coronavirus or SARS-CoV-2. The assays will be designed for use on any of the company’s high-throughput Access family of immunoassay systems, including the Access 2 and DxI series installed globally. After finalizing the assays, Beckman Coulter plans to submit them for the FDA's Emergency Use Authorization.

Beckman Coulter’s diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the world. Research has shown that after infection with SARS-CoV-2, viral antigens stimulate the body's immune system to produce antibodies that can be detected with IgM and IgG tests.

"Antibody assays play a critical role in understanding the measure of immunity an individual has developed against SARS-CoV-2," said Kathleen Orland, senior vice president and general manager for Beckman Coulter's chemistry and immunoassay business. "This type of understanding could help determine the identification of those who would require a vaccine once available or when an infected individual could safely return to work."

"With the ability to assess a patient's immunity to SARS-CoV-2, this testing modality may enable clinicians to clear hospital staff, emergency responders, and others to get back to work with an indication that have had prior exposure and therefore may have immunity to the disease," said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. "This test also could allow those without immunity to be identified and kept safe until the pandemic subsides."

Related Links:
Beckman Coulter


Print article

Channels

Microbiology

view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.